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Background:The current proposedmodel of colorectal tumorigenesis is based primarily on
CpG islandmethylator phenotype (CIMP), microsatellite instability (MSI), KRAS, BRAF, and
methylation status of 0-6-Methylguanine DNA Methyltransferase (MGMT ) and classifies
tumors into five subgroups.The aim of this study is to validate this molecular classification
and test its prognostic relevance. Methods:Three hundred two patients were included in
this study. Molecular analysis was performed for five CIMP-related promoters (CRABP1,
MLH1, p16INK4a, CACNA1G, NEUROG1), MGMT, MSI, KRAS, and BRAF. Methylation
in at least 4 promoters or in one to three promoters was considered CIMP-high and
CIMP-low (CIMP-H/L), respectively. Results: CIMP-H, CIMP-L, and CIMP-negative were
found in 7.1, 43, and 49.9% cases, respectively. One hundred twenty-three tumors (41%)
could not be classified into any one of the proposed molecular subgroups, including 107
CIMP-L, 14 CIMP-H, and two CIMP-negative cases.The 10 year survival rate for CIMP-high
patients [22.6% (95%CI: 7–43)] was significantly lower than for CIMP-L or CIMP-negative
(p = 0.0295). Only the combined analysis of BRAF and CIMP (negative versus L/H) led
to distinct prognostic subgroups. Conclusion: Although CIMP status has an effect on
outcome, our results underline the need for standardized definitions of low- and high-
level CIMP, which clearly hinders an effective prognostic and molecular classification of
colorectal cancer.
Keywords: CpG island methylator phenotype, colorectal cancer, DNA methylation, BRAF, prognosis
INTRODUCTION
Jass (2007) proposed amolecular classification of colorectal cancer
based predominantly on five features: CpG island methylator phe-
notype (CIMP),microsatellite instability (MSI),KRAS,BRAF, and
methylation status of 0-6-Methylguanine DNA Methyltransferase
(MGMT ). The new classification was composed of five molecular
subtypes, with the largest group including mostly CIMP-negative,
chromosomally instable (CIN), microsatellite stable (MSS) col-
orectal cancers (57% of cases). In addition, CIMP-low (CIMP-
L), KRAS mutated, MGMT methylated, MSS/ MSI-low (MSI-L)
cancers were predicted in 20% of cases, while CIMP-H, BRAF
mutated, MSI-H tumors in 12%, CIMP-H, BRAF mutated, chro-
mosomally stable, MSS/MSI-L in 8%, and finally, the hereditary
Lynch syndrome CIMP-negative, BRAF mutation-negative, chro-
mosomally stable, and MSI-H cancers found in 3% of all cases.
Indeed, these new subgroupings form the basis of the current
model of colorectal tumorigenesis.
To date, the prognostic relevance of Jass’s proposed groupings,
particularly those arising in the sporadic context, has not yet been
tested. As singlemolecular entities,KRAS mutations andMSI have
been intensively investigated,while mutations in BRAF and analy-
sis of CIMP are fewer (Andreyev et al., 1998; Boland and Goel,
2010). Less than a handful of studies have evaluated the prognostic
relevance of MGMT (Shima et al., 2011). CIMP-H andMSI-H col-
orectal cancers seem to share similar features including proximal
tumor location, mucinous histological type, poorer tumor grade,
and BRAF mutation, but they may be inter-dependent in terms of
their prognostic effects (Ogino et al., 2009; Sanchez et al., 2009;
Dahlin et al., 2010). Patients with MSI-H cancers may benefit from
a decreased rate of distant metastasis and longer survival time
when compared to their MSS counterparts (Kloor et al., 2010)
whereas patients with CIMP-H cancers particularly in the MSS
context seem to have a considerably more unfavorable outcome
(Ward et al., 2003; Dahlin et al., 2010; Kloor et al., 2010). Also,
BRAF mutated cancers may lead to poorer survival time in MSS
cancers only (Samowitz et al., 2006).
The aim of this study was first to classify a cohort of 302 col-
orectal cancers according to the proposed molecular classification
based on CIMP, MGMT methylation, KRAS and BRAF mutation,
and MSI and then, to test its prognostic value.
MATERIALS AND METHODS
PATIENTS
About 1420 primary pre-operatively untreated, unselected spo-
radic colorectal cancer patients treated between the years 1987
and 1996 were initially included in this study. Hematoxylin and
eosin (H&E) stained slides were retrospectively collected from
the Institute of Pathology, University Hospital of Basel, the Insti-
tute of Clinical Pathology, Basel, Switzerland, and the Insti-
tute of Pathology, Stadtspital Triemli, Zürich, Switzerland. From
this larger subgroup, only 600 paraffin-embedded tissue blocks
could be retrieved. Histopathological criteria were reviewed by
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an experienced gastrointestinal pathologist. The tumor border
configuration (pushing/expanding or infiltrating) as well as the
presence of peritumoral lymphocytic inflammation at the inva-
sive tumor front were scored according to Jass (1986). Clinical data
including patient age at diagnosis, tumor location, and follow-up
were retrieved from patient records. Clinical outcome of interest
was cancer-specific survival time. Censored observations included
patients who were alive at the last follow-up, died for reasons other
than colorectal cancer or were lost to follow-up. Patient character-
istics are summarized in Table 1. The use of material for this study
was approved by the ethics committee of the University Hospital
of Basel.
ASSAY METHODS
DNA isolation, mutation, and microsatellite instability analysis
In order to identify regions for punching and DNA extraction,
neoplastic, and adjacent non-neoplastic tissue areas were marked
on the H&E slide by an experienced pathologist (A.L) with pens of
two different colors. Only blocks with >70% tumor content were
used for this purpose.
Table 1 | Patient characteristics (n =337).
Freq (%)
Age (years; n =313) Mean, range 69.9 (42–95)
Tumor diameter (mm; n =307) Mean, range 51.3 (5–160)
Gender (n =337) Female 181 (53.7)
Male 156 (46.3)
Tumor location (n =335) Left-sided 210 (62.7)
Right-sided 125 (37.3)
Histological subtype (n =337) Non-mucinous 314 (93.2)
Mucinous 23 (6.8)
pT classification (n =331) pT1–2 72 (21.8)
pT3–4 259 (78.2)
pN classification (n =326) pN0 177 (54.3)
pN1–2 149 (45.7)
Tumor grade (n =331) G1-2 310 (93.7)
G3 21 (6.3)
Vascular invasion (n =331) Absent 233 (70.4)
Present 98 (29.6)
Tumor border (n =329) Pushing 98 (29.8)
Infiltrating 231 (70.2)
Peritumoral lymphocytic
inflammation (n =331)
Absent 255 (77.0)
Present 76 (23.0)
KRAS (codon 12 and 13; n =325) Wild-type 226 (69.5)
Mutation 99 (30.5)
BRAF (codon V600E; n =314) Wild-type 272 (86.6)
Mutation 42 (13.4)
MSI status (n =337) Stable/instable–low 281 (83.4)
Instable–high 56 (16.6)
CIMP (n =337) Negative 168 (49.9)
Low 145 (43.0)
High 24 (7.1)
MGMT (n =337) Non-methylated 225 (66.8)
Methylated 112 (33.2)
Genomic DNA was obtained from both primary tumors and
adjacent non-neoplastic tissues using NucleoMag 96 Tissue Kit
(Macherey Nagel) protocol and processed in the Xiril X-100
robot (Xiril, Hombrechtikon, Switzerland). Briefly, punched tis-
sue was lysed in proteinase K. B-beads and MB2 buffer were
added to the cleared lysate, shaken for 5min at RT. The super-
natant was removed and MB3 buffer was added followed by
shaking and supernatant removal. The genomic DNA was eluted
with MB6 buffer. Genomic DNA was amplified by PCR using
AmpliTaq Gold polymerase (Applied Biosystems). KRAS (exon 2
codon 12 and 13) and BRAF (exon 15 codon 600) were ampli-
fied by a first and a nested PCR. Residual primers were removed
using the EXOSAPit (Amersham). Samples were then subjected
to direct sequencing of single-stranded PCR products using the
BigDye® Terminator v1.1 cycle sequencing kit (Applied Biosys-
tems, Foster City, CA, USA) and the ABI Prism® 3130 genetic
analyzer (Applied Biosystems). All products were sequenced bi-
directionally. Analysis of MSI status was based on the multiplex
amplification of the five microsatellites (BAT25, BAT26, D2S123,
D5S346,D17S250). An initial denaturation step at 95˚C for 10min
was followed by 42 cycles at 95˚C for 40 s, 54˚C for 40 s, and
72˚C for 60 s. For the analysis, 1μl of the DNA weight marker
ROX 500 (Applied Biosystem) was added and 10μl of deion-
ized formamide in 3μl of the PCR amplified solution. DNA
was denaturated by incubation for 2min at 95˚C. The POP-7
polymer solution (Applied Biosystem) was used for the elec-
trophoresis on the ABI Prism® 3130 genetic analyzer (Applied
Biosystems). MSS and MSI-L status were defined as instability at
zero and one microsatellite, respectively. MSI-H was characterized
by the presence of instability in 40% (≥2 markers; Umar et al.,
2004).
DNA bisulfite treatment
DNA denaturation and bisulfite conversion were processed into
one-step using the EZ-96 DNA Methylation-GoldTM Kit (Cat.
No. D5007, Zymo Research Corporation) according to manufac-
turer’s instructions. Briefly, 130μl of the CT conversion reagent
were added to 20μl of each DNA sample in a conversion plate.
The plates were sealed with the provided film and the conversion
plate transferred to a thermal cycler running under the following
steps: 98˚C for 10min, 53˚C for 4 h, storage at 4˚C. Four hun-
dred microliters of M-Binding Buffer were added to the wells of
a Silicon-A™Binding Plate. The samples were transferred from
the conversion plate to the wells of the Silicon-A™binding plate
and centrifuged at 3,000× g for 5min. Each well of the plate
was washed using 400μl of M-wash buffer. The samples were
centrifuged at 3,000× g for 5min. 200μl of M-Desulphonation
buffer was added to each and the plate was placed at room tem-
perature for 20min followed by centrifugation (3,000× g for
5min). Two consecutive steps including washing (400μl of M-
wash Buffer) and centrifugation (3,000× g for 5min) were per-
formed. The Silicon-A™binding plate was placed onto an elution
plate and 30μl of M-Elution buffer was directly added to each
well. 5min later, the samples were centrifuged at 3,000× g for
3min to elute the DNA. For control of DNA methylation, Univer-
sal Methylated Human DNA Standard was used (Cat. No. D5011,
Zymo Research Corporation).
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Amplification of modified DNA
For the first and the nested PCR, 50 cycles of amplification was
performed. Two microliters of the modified DNA was added in a
volume of 25μl containing the dNTPs (0.2mM final), PCR Gold
Buffer (1× final,Applied Biosystem),PCRprimers (0.12μM), and
0.2μl of Taqpolymerase (ampliTaqGold,AppliedBiosystem). The
nested PCR is performed under the same condition by addition of
1μl of the amplicon in 25μl of master mix.
Promoter methylation was assayed for the five CIMP-related
genes [CRABP1 (HGNC: 2338), MLH1, p16INK4a, CACNA1G,
NEUROG1] as well as forMGMT. For the first and the nested PCR,
50 cycles of amplification were performed. Primer sequences are
listed in Table 2.
Pyrosequencing and CpG site quantification
Three microliters of Sepharose beads were mixed together with
40μl of binding buffer and 22μl of water and mixed in an Eppen-
dorf tube. Sixty microliters of this mix was added to 20μl of PCR
products in a 96 well plate and agitated at 1400 rpm for 5min. The
PyroMark Q96 Plate was filled with 0.3μM of sequencing primer
in 40μl of annealing buffer. The washed were performed using
the vacuum station according to themanufacturer instruction. For
annealing the samples to sequencing primers, the temperature was
increased to 80˚C for 2min and rapidly cooled to room temper-
ature. Plates were then ready for processing in the PyroMarkQ96
instrument.
Pyrosequencing of the purified single-stranded PCR prod-
ucts and CpG site quantification was accomplished by the Pyro-
MarkQ96 and related software (Qiagen). Four to sixCpG siteswere
evaluated for each gene in both neoplastic and corresponding non-
neoplastic tissue. Since this method is quantitative, each CpG site
is assigned a percentage of methylation. The final CpG score for
the tumor or non-neoplastic tissue is represented as the average
percentagemethylation across all CpG sites for that gene.A tumor-
specific methylation score can then be assigned by subtracting out
any background methylation from the adjacent non-neoplastic
tissue from the tumor’s CpG score. This method for calculation
is summarized in Figure 1. Although the non-neoplastic mucosa
is expected to be non-methylated, age-related methylation, and
background can still occur (Issa, 2000). The threshold tumor-
specific methylation score for considering a case as methylation
positive was>30% (minimal difference between tumor and non-
neoplastic mucosa). This cut-off score was based on the measured
and theoretical percentage of methylation observed at different
numbers of PCR amplification cycles using commercially available
DNA (unmethylated and 100% methylated, Qiagen) and combi-
nations of the two, resulting in varying degrees of methylation
(0, 0.1, 0.3, 1, 3, 10, 30, and 100%). According to these findings,
background methylation can be 10% suggesting that a minimal
difference in methylation of 20% (10% for tumor and 10% for
non-neoplastic) should be used to define methylation-positivity
above background. Here, we have used a more stringent crite-
rion of 30% to ensure with even greater certainty a significant
degree of methylation. CIMP-H was defined as methylation in
≥4/5 gene loci, while CIMP-L and CIMP-negative were defined
as methylation in one to three genes and no gene methylation,
respectively.
STATISTICAL ANALYSIS
Univariate survival analysis was performed using the Kaplan–
Meier method and log-rank test (SAS V9.2; The SAS Institute,
Cary, NC, USA). Re-classification of patients into prognostic
molecular subgroups was performed using classification and
regression tree (CART) analysis with survival status at 10 years
follow-up as outcome of interest. To measure the classification
error as a function of tree size, 10-fold cross-validation exper-
iments were performed (DTREG Predictive Modeling Software,
www.dtreg.com).
RESULTS
FREQUENCY OF MOLECULAR FEATURES
From the 600 cases initially investigated, molecular characteri-
zation for CIMP was possible in 337 patients. This was due to
the lower quality of DNA which could be extracted from older
paraffin-embedded tissues. The frequency of methylation using
the proposed criteria were 16% for CDKN2A, 14% for CACNA1G,
17% for MLH1, 18% for CRABP1, 22% for NEUROG1. Twenty-
four patients (7.1%) were CIMP-H, 145 (43%) CIMP-L, and 168
(49.9%) CIMP-negative. KRAS and BRAF mutational analysis
could be made in 325 and 314 patients, respectively while MGMT
and MSI analysis was possible in all 337 cases. Thirty-three percent
of patients were methylated for MGMT and 16.6% had MSI-H
tumors. All molecular features could be analyzed in 304 cases. The
frequencies of KRAS and BRAF mutation were 30.5 and 13.3%,
respectively while of MSI and MGMT methylation was 16.6 and
33.2%.
CLASSIFICATION INTO PROPOSED SUBGROUPS
Tumors were then classified into each of Jass Groups 1–5
(Figure 2). In Jass Group 1, only six patients (2%) were CIMP-
H, BRAF mutated and MSI-H, compared to the predicted 12%.
In Group 2, there were five patients (2%) with CIMP-H, BRAF
mutatedMSS/MSI-L cancers, compared to the predicted 8%.Next,
13 cases (4%) could be classified into Jass Group 3 containing
CIMP-L, MSS/MSI-L, KRAS mutated, and MGMT methylated
tumors, rather than the predicted 20%. Group 4 remained the
largest group with 45% of patients (n = 137) showing CIMP-
negativity, MSS/MSI-L. Finally, Group 5 contained 18 patients
(6%) with CIMP-negative, BRAF WT, MSI-H cancers. Inter-
estingly, 41% (n = 124) of tumors could not be classified into
any of the proposed groupings including the remaining 107
(35.4%) CIMP-L cases, 14 CIMP-H, BRAF WT (4.6%), and four
CIMP-negative, BRAF mutated, MSI-H (1.3%).
PROGNOSTIC IMPACT OF CIMP AND MGMT
The median survival time of the entire cohort was 63 (95%CI:
46–84) months. Patients with CIMP-H colorectal cancers were
found to have a significantly lower 10 year survival rate [22.6%
(95%CI): 7–43)] compared to both CIMP-L [34.8% (95%CI):
26–43] and CIMP-negative [43.4% (95%CI): 34–53] cancers
(p = 0.0248; Figure 3A). This unfavorable prognostic effect
occurred in MSS/MSI-L (p = 0.0532) and showed a trend in
MSI-H (p = 0.2515; Figures 3B,C). In contrast, no difference in
survival time was noted for patients with MGMT methylated or
unmethylated tumors (p = 0.4966; Figure 3D).
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FIGURE 1 | Method of calculation used for determining methylation
status.The pyrograms show percent methylation at five CpG sites in a
colorectal cancer and its corresponding normal mucosa; the individual CpG
scores are averaged for each. The mean percent methylation from the
normal tissue is subtracted from the mean percent methylation of the
tumor to give a tumor-specific methylation score. If this final score is
≥30%, then the tumor is considered methylated, otherwise it is
considered negative for methylation.
FIGURE 2 | Attempt to classify 302 colorectal cancers into the
proposed Jass Groups 1–5. Forty-one percent of all cases could not be
assigned to any one of these subgroups. In parentheses, the asterisk
identifies the predicted percentage of patients belonging to each group.
CLASSIFICATION AND REGRESSION TREE ANALYSIS
Of the 304 fully molecularly characterized patients, 302 had sur-
vival time information and were entered CART analysis. This
approachwas used to classify patients into prognostic groups using
10 year survival as the clinical endpoint (Figure 4A). BRAF gene
mutationwas identified as themost important parameter and clas-
sified as a single group. Patients with BRAF WT tumors were fur-
ther discriminated based onCIMP status; patientswith anymethy-
lation of CpG islands (CIMP-H and CIMP-L) formed a separate
prognostic group. CIMP-negative patients were further subdi-
vided by KRAS gene status. The remaining classification by MSI or
MGMT methylation yielded little additional discrimination. The
frequency of these subgroups is shown in Figure 4B. Ten year sur-
vival for the most important subgroups underline a rate of 10%
(95% CI: 1–32; n = 30) for patients with BRAF mutated tumors,
followed by 38% (95%CI: 29–47; n = 118) for BRAF WT, CIMP-
H, or CIMP-L tumors, then 50% (95%CI: 32–62; n = 112) for
BRAF WT, CIMP-negative, KRAS WT cases, and 55% (95%CI:
23–72; n = 42) for BRAF WT, CIMP-negative, KRAS mutated
cases. Hence, three major groups of patients were identified:BRAF
mutated, CIMP-H or CIMP-L, and CIMP-negative (p = 0.034).
DISCUSSION
Our results suggest that Jass’s model of colorectal cancer can-
not effectively classify patients from the institutes included in this
study into molecular subgroups. Here, we analyze the reasons for
this discordance.
We used pyrosequencing rather than MethyLight or
methylation-specific PCR (MSP) to quantify methylation at CpG
islands. This is a novel yet validated method for investigating
CpG site methylation from paraffin-embedded tissues (Colella
et al., 2003; Tost et al., 2003; Potapova et al., 2011). In contrast
to MethyLight and MSP, each CpG site is assigned a percentage of
methylation. This has several advantages; among others, it allows
us to take into consideration the background methylation of the
adjacent non-neoplastic tissue and assign a tumor-specific methy-
lation score by subtracting out this signal. This is particularly
interesting in the case of CDKN2A where age-related methylation
can occur more frequently (Toyota et al., 1999).
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FIGURE 3 | Kaplan–Meier survival curves showing survival time differences for patients with CIMP-H, CIMP-L, and -negative tumors (A) in the whole
patient cohort, (B) in microsatellite stable or instable-low (MSS/MSI-L) and (C) in microsatellite instable-high (MSI-H) cases, and (D) for patients
stratified by MGMT status.
FIGURE 4 | (A) Analysis of the five molecular features using classification and
regression tree analysis shows the hierarchy of most discriminating
alterations and prognostic subgroups, namely subgroup 1: BRAF mutation,
subgroup 2: CIMP-high, and CIMP-low and subgroup 3: CIMP-negative. KRAS,
MGMT, and MSI contribute only little additional prognostic information. (B)
Frequencies of each new subgroup.
In this study we evaluated the following five CIMP genes:
CACNA1G, NEUROG1, CDKN2A, CRABP1, and MLH1. Not
only has this same panel been used in previous studies (Ogino
et al., 2006), but a comparison study of the performance char-
acteristics of these genes has shown them to be reliable for the
detection of CIMP phenotype (Ogino et al., 2007). Although we
used a stringent criterion for determining methylation-positivity
of each gene (minimal 30% difference between tumor and
non-neoplastic CpG methylation), we nonetheless obtain rates
comparable to those published by others. Our frequency of 16%
for CDKN2A is slightly lower than that of Ogino and Nosho using
MethyLight assays (29, 30%) but similar to Ahn et al. (2011)
and also Yu et al. (2008) using pyrosequencing (16 and 20%,
respectively; Ogino et al., 2007; Nosho et al., 2008). Our find-
ing of methylation in 33% MGMT, 22% for NEUROG1, and
14% for CACNA1G is similar to the 38, 32, and 13% reported
Frontiers in Oncology | Gastrointestinal Cancers February 2012 | Volume 2 | Article 7 | 6
Zlobec et al. Molecular classification of colorectal cancer
by Nosho and Lee while the 17% obtained for MLH1 is also
within the expected range documented by others (6–28%; Ogino
et al., 2007; Lee et al., 2008; Nosho et al., 2008; Ahn et al.,
2011).
We defined CIMP-H and CIMP-L as at least four/five and one
to three methylated genes, respectively. Dahlin et al. (2010) char-
acterized CIMP-L and CIMP-H as hypermethylation in one to
five and six to eight genes using the MethyLight method. Jover
et al. (2011) considered CIMP+ as aberrant methylation in at
least three/five genes (25% CIMP+ rate). Kim et al. (2010), also
using pyrosequencing show a CIMP+ rate of 35.8% when con-
sidering hypermethylation of at least two/seven genes while Van
Rijnsoever et al. (2003) report a 32% CIMP+ rate referring to at
least two/three methylated sites. Finally, Ogino et al. (2009) used
an eight-marker panel and defined CIMP-H as at least six/eight
methylated promoters by MethyLight assays. There is to date
no consensus regarding the number of methylated genes to be
included in the definition of CIMP.
Our frequency of CIMP-H and -L is 7.1 and 43%, respec-
tively. Dahlin et al. (2010) evaluated three prospective European
population-based cohorts (together termed the Northern Sweden
Health andDisease Study,NSHDS) followed by a second expanded
series (Colorectal cancer in Umeo Study, CRUMS) including 190
and 414 patients. Stratifying by MSS status, they report a 7.4 and
6.8% CIMP-H rate in the MSS and MSI tumors of the NSHDS and
3.0 and 8.8% CIMP-H rate for MSS and MSI tumors, respectively
in the larger CRUMS. Therefore, although the frequency of CIMP-
H in this study is lower than expected, it is in accordance with
these larger European studies. More importantly, the poor prog-
nostic effect observed here in patients with CIMP-H and CIMP-L
tumors in comparison to those showing CIMP-negativity agrees
with several works from other authors (Ward et al., 2003; Kim
et al., 2009; Dahlin et al., 2010). In addition, our findings show no
association of MGMT methylation with prognosis, a result which
was also recently observed by Shima et al. (2011).
A recent review by Curtin et al. (2011), stresses that in con-
trast to the relatively straightforward determination of MSI tumor
status, a consensus panel of CpG sites for CIMP determination
has not yet been made. To date, studies evaluating CIMP have
shown considerable variability in the selection of CIMP-related
promoters, definition of threshold values, and variation in the
number of methylated genes to define CIMP-L and CIMP-H. In
this study 41% of all cases could not be classified into any one
of Jass’s five proposed molecular subgroups. Eighty-six percent of
these unclassifiable cases were CIMP-L and 11% CIMP-H. This
finding stresses again that the definition of CIMP status can sig-
nificantly compromise the validation of a molecular classification
of colorectal cancer based on three categories of CIMP. One possi-
bility would be to evaluate CIMP-negative versus CIMP+ tumor,
regardless of the degree of methylation. Supporting this further,
our study here shows that in the case of BRAF wild-type patients,
CIMP-L, and H cancers segregate together in CART analysis.
Although evidence suggests that CIMP not only plays a major
role in the pathogenesis but also in the prognosis of patients
with colorectal cancer, an effective classification is clearly hindered
by the definition of high and low-level CIMP. The selection of
promoter regions, number of CpG sites, analysis method and cut-
off values leading to standardized definitions of CIMP status all
warrant considerable investigation.
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